Savara Inc. (SVRA) Dividend History

Company News

• Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference

  Savara, a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced its participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference, where the company will host 1x1 meetings and present.

  Benzinga
• Savara Announces Participation in the Upcoming Citizens Life Sciences Conference

  Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced its participation in the upcoming Citizens Life Sciences Conference, where the company's management team will host 1x1 meetings and participate in a fireside chat.

  Benzinga
• XChain, VARA’s Exclusive Transaction Monitoring Partner, Readies Rollout for Regional and Global VASPs

  XChain, a digital assets monitoring firm, is partnering with Dubai's VARA to provide transaction monitoring services for Virtual Asset Service Providers (VASPs) in the region. The partnership aims to establish a reliable and transparent monitoring framework to enable VASPs to manage their risk and compliance effectively.

  GlobeNewswire Inc.
• Savara Announces Participation in Upcoming Healthcare Conferences

  Savara, a clinical-stage biopharmaceutical company focused on rare respiratory diseases, announced its participation in upcoming healthcare conferences, where it will present its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

  Benzinga
• Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of "The Balancing Act®" Airing on Lifetime® TV

  Savara, a biopharmaceutical company, announced that a new episode of The Balancing Act® on Lifetime TV will feature autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung disease. The episode aims to increase awareness and provide insights into the diagnostic journey of an aPAP patient.

  Benzinga